Darren Hodgson

5.3k total citations · 3 hit papers
73 papers, 3.1k citations indexed

About

Darren Hodgson is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Darren Hodgson has authored 73 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 32 papers in Molecular Biology and 24 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Darren Hodgson's work include PARP inhibition in cancer therapy (33 papers), Cancer Genomics and Diagnostics (22 papers) and BRCA gene mutations in cancer (17 papers). Darren Hodgson is often cited by papers focused on PARP inhibition in cancer therapy (33 papers), Cancer Genomics and Diagnostics (22 papers) and BRCA gene mutations in cancer (17 papers). Darren Hodgson collaborates with scholars based in United Kingdom, United States and Canada. Darren Hodgson's co-authors include Anitra Fielding, J. Carl Barrett, Jonathan A. Ledermann, Stuart Spencer, Brian Dougherty, Charlie Gourley, Maria Orr, Philipp Harter, Michael Friedländer and Tamar Safra and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and Cancer Research.

In The Last Decade

Darren Hodgson

71 papers receiving 3.1k citations

Hit Papers

Olaparib maintenance therapy in patients with platinum-se... 2014 2026 2018 2022 2014 2016 2018 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
    2014 1.1k citations Jonathan A. Ledermann, Philipp Harter et al. The Lancet Oncology profile →
  2. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
    2016 309 citations Jonathan A. Ledermann, Philipp Harter et al. The Lancet Oncology profile →
  3. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
    2018 281 citations Noel W. Clarke, Paweł Wiechno et al. The Lancet Oncology profile →

Peers

Darren Hodgson
M. William Audeh United States
Karin Bowen United States
Sreenivasa Nattam United States
Holger W. Hirte Canada
Sarah Runswick United Kingdom
Matthew Boente United States
Jacqui Rowbottom United Kingdom
Carrie A. Adelman United States
Kosei Hasegawa Japan
Patricia A. Shaw Canada
M. William Audeh United States
Darren Hodgson
Citations per year, relative to Darren Hodgson Darren Hodgson (= 1×) peers M. William Audeh

Countries citing papers authored by Darren Hodgson

Since Specialization
Citations

This map shows the geographic impact of Darren Hodgson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darren Hodgson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darren Hodgson more than expected).

Fields of papers citing papers by Darren Hodgson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darren Hodgson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darren Hodgson. The network helps show where Darren Hodgson may publish in the future.

Co-authorship network of co-authors of Darren Hodgson

This figure shows the co-authorship network connecting the top 25 collaborators of Darren Hodgson. A scholar is included among the top collaborators of Darren Hodgson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darren Hodgson. Darren Hodgson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hong, Tae Hee, Soohyun Hwang, Chris Abbosh, et al.. (2025). Association of pre-surgical circulating tumor DNA detection, use of sublobar resection with risk of recurrence in stage I non-small cell lung cancer. European Journal of Cancer. 217. 115237–115237. 1 indexed citations
2.
Juul, Randi Istrup, Iver Nordentoft, Karin Birkenkamp‐Demtröder, et al.. (2025). Low T cell diversity associates with poor outcome in bladder cancer: A comprehensive longitudinal analysis of the T cell receptor repertoire. Cell Reports Medicine. 6(5). 102101–102101. 1 indexed citations
3.
4.
Bossé, Yohan, Abhijit Dasgupta, Violeta Beleva Guthrie, et al.. (2024). Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer. Cancer Letters. 594. 216984–216984. 6 indexed citations
5.
Abbosh, Chris, Darren Hodgson, Gary J. Doherty, et al.. (2024). Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer. Trends in cancer. 10(7). 643–654. 18 indexed citations
6.
7.
Reck, Martin, Daniel P. Gale, David H. Harpole, et al.. (2023). LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial. Annals of Oncology. 34. S1300–S1300. 23 indexed citations
8.
Stetson, Daniel, Gregory T. Jones, Giovanni Marsico, et al.. (2023). Abstract 3384: Evaluation of a tumor informed MRD assay with contrived breast cancer samples. Cancer Research. 83(7_Supplement). 3384–3384. 1 indexed citations
9.
Lai, Zhongwu, Ethan S. Sokol, Mingchao Xie, et al.. (2022). Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets. BMC Cancer. 22(1). 13–13. 28 indexed citations
10.
Willis, Sophie E., C Winkler, Martine P. Roudier, et al.. (2021). Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. British Journal of Cancer. 125(12). 1666–1676. 31 indexed citations
11.
Hodgson, Darren, Brian Dougherty, Zhongwu Lai, et al.. (2018). Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. British Journal of Cancer. 119(11). 1401–1409. 167 indexed citations
12.
Clarke, Noel W., Paweł Wiechno, B. Yа. Alekseev, et al.. (2018). Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Oncology. 19(7). 975–986. 281 indexed citations breakdown →
13.
Brant, Roz, Alan Sharpe, Jonathan R. Dry, et al.. (2016). Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors. Clinical Cancer Research. 23(6). 1471–1480. 17 indexed citations
14.
Nomura, Hiroyuki, Fumio Kataoka, Daisuke Aoki, et al.. (2016). Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer. Cancer Biomarkers. 16(1). 145–152. 9 indexed citations
15.
Kilgour, Elaine, Helen K. Angell, K.-M. Kim, et al.. (2016). Programmed death-ligand 1 (PD-L1) and immune infiltrates are prognostic for better outcome and enriched in the ATM (ataxia telangiectasia mutated)-low segment of gastric cancer (GC). Annals of Oncology. 27. vi212–vi212. 1 indexed citations
16.
17.
Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2014). Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer. Obstetrical & Gynecological Survey. 69(10). 594–596. 14 indexed citations
18.
Dearden, Simon, Chris Harbron, Darren Hodgson, et al.. (2013). Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 462(3). 269–279. 20 indexed citations
19.
Hodgson, Darren, et al.. (2008). Biomarkers in oncology drug development. Molecular Oncology. 3(1). 24–32. 23 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. William Audeh Breakdown of academic impact, for papers by Karin Bowen Breakdown of academic impact, for papers by Sreenivasa Nattam Breakdown of academic impact, for papers by Holger W. Hirte Breakdown of academic impact, for papers by Sarah Runswick Breakdown of academic impact, for papers by Matthew Boente Breakdown of academic impact, for papers by Jacqui Rowbottom Breakdown of academic impact, for papers by Carrie A. Adelman Breakdown of academic impact, for papers by Kosei Hasegawa Breakdown of academic impact, for papers by Patricia A. Shaw
Rankless by CCL
2026